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Background: Despite modern advances in treatment, skin cancer is still one of the most common causes of death
in the western countries. Chemotherapy plays an important role in melanoma management. Tamoxifen has been
used either alone or in- combination with other chemotherapeutic agents to treat melanoma. However, response
rate of tamoxifen as a single agent has been comparatively low. In the present study, we investigated whether
treatment with methyl-β-cyclodextrin (MCD), a cholesterol depleting agent, increases the efficacy of tamoxifen in
melanoma cells.
Methods: This was a two-part study that incorporated in vitro effects of tamoxifen and MCD combination by
analyzing cell survival, apoptosis and cell cycle analysis and in vivo antitumor efficacy on tumor isografts in
C57BL/6J mice.
Results: MCD potentiated tamoxifen induced anticancer effects by causing cell cycle arrest and induction of
apoptosis. Sensitization to tamoxifen was associated with down regulation of antiapoptotic protein Bcl-2,
up-regulation of proapoptotic protein Bax, reduced caveolin-1 (Cav-1) and decreased pAkt/pERK levels.
Co-administration of tamoxifen and MCD caused significant reduction in tumor volume and tumor weight in mice
due to enhancement of drug uptake in the tumor. Supplementation with cholesterol abrogated combined effect of
tamoxifen and MCD.
Conclusion: Our results emphasize a potential synergistic effect of tamoxifen with MCD, and therefore, may
provide a unique therapeutic window for improvement in melanoma treatment.
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Melanoma, a dreaded form of skin cancer, affects deeper
skin layers of the body and spreads rapidly to other tissues
and organs [1]. Chronic exposure of skin to sunlight or
UV radiation is a major risk factor for the development
of melanoma characterized by alterations in the synthesis
of melanin pigment [2,3]. Chemotherapeutic drugs, radi-
ation and immunotherapy have been widely used to treat
melanoma [4,5]. In spite of these options, the median sur-
vival rate of melanoma patients is approximately 6 months* Correspondence: manojkbhat@nccs.res.in
1National Centre for Cell Science, NCCS Complex, Ganeshkhind, Pune 411007,
India
Full list of author information is available at the end of the article
© 2014 Mohammad et al.; licensee BioMed Ce
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.and hardly 5% of these patients may survive upto 5 years
[6]. Tamoxifen (TAM) is a key member of the selective
estrogen receptor modulator family used for the treatment
of breast cancer, glioma, cholangiocarcinoma, ovarian
cancer and leukemia [7-11]. Tamoxifen inhibits estrogen re-
ceptor (ER), although it may exert its effect in ER independ-
ent manner too. While the expression of ER in melanoma
remains ambiguous, the anticancer effect of tamoxifen has
been studied in various melanoma cells [12-14]. Tamoxifen
in- combination with other drugs has shown marginal suc-
cess in combating melanoma [15,16]. Failures are attributed
to the development of resistance due to limited drug distri-
bution within the tumor cells. Therefore, we hypothesizedntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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eventually enhance the therapeutic index.
Plasma membrane contains nanometer-sized dynamic
microdomains enriched in cholesterol, sphingolipids and
gangliosides. These microdomain structures are integral
to the regulation of influx or efflux of drugs. Depletion
of membrane cholesterol disrupts integrity of lipid rafts
and concurrently enhances the permeability of ions and
small non-electrolytes [17,18]. Among various cholesterol
depleting agents available, methyl-β-cyclodextrin (MCD),
a highly water soluble cyclic heptasaccharide consisting
of β-[1-4] glucopyranose unit, is the most effective agent
for depletion of cholesterol from the cells [19,20]. We
and others have shown that MCD or its modified forms
enhance the cytotoxic effect of various chemotherapeu-
tic drugs [21-23].
We demonstrate that in comparison to tamoxifen alone,
MCD treatment enhances the sensitivity of cells towards
tamoxifen and thus establishes a promising new strategy
for improvement in the outcome of chemotherapy.
Results
Methyl-β-cyclodextrin enhances the susceptibility of A375
and B16F10 cells to tamoxifen
Tamoxifen treatment causes a dose-dependent decrease
in the survival of A375, B16F10 and B16F1 cells and
IC50 was calculated to be 30 μM, 40 μM and 30 μM re-
spectively (Additional file 1: Table S1). We checked the
effect of MCD by treating A375 and B16F10 cells with
2.5 mM of MCD for 1 h or 4 h and no significant change
in cell cycle progression, cell survival and LDH release was
observed at 2.5 mM dose of MCD for 4 h. MCD at 5 mM
concentration was toxic (Additional file 2: Figure S1)
and similar results were also obtained in B16F1 cells
(Additional file 3: Figure S2A) by cell survival assay. For
all subsequent experiments, 2.5 mMMCD was used.
We screened the effect of various chemotherapeutic drugs
like carboplatin (Carb), 5-fluorouracil (5-FU), doxorubicin
(DOX), tamoxifen (TAM) and dacarbazine (DTIC) in-
combintaion with MCD in A375 and B16F10 cells. While
MCD specifically enhanced the cytotoxicity of tamoxifen
and DTIC, it did not significantly enhance cell death in-
duced by Carb, 5-FU and DOX (Additional file 4: Figure S3)
(Additional file 5: Figure S4) in A375 and B16F10 cells.
Although, DTIC is the preferred drug in melanoma
treatment, which is used at 5–10 times the dose of
tamoxifen [12], it is desirable to define a strategy to
enhance the therapeutic efficacy of tamoxifen, a well known
ER antagonist. We investigated the combinatorial effect of
IC50 concentration of tamoxifen with MCD. Expectedly, at
IC50 concentration of tamoxifen, cell survival diminished by
50%, which reduced to ≤35% (A375) and 40% (B16F10) in
the presence of MCD and these results are clearly seen in
long term clonogenic assay (Figure 1A, D). Combination oftamoxifen and MCD not only inhibited the proliferation of
melanoma cells (A375 and B16F10) but also other human
cell lines, viz., MCF-7 (breast cancer cell line) and HeLa
(cervical cancer cell line) in a tamoxifen dose dependent
manner (Figure 1B, E and G, H). To determine the long
term effect of tamoxifen and MCD combination by clono-
genic cell survival assay, cells were treated for 24 h with
both drugs together or either agent alone and allowed
to grow for 10–15 days. Number of colonies was reduced
significantly in- combination treatment as compared to
either agent alone (Figure 1C, F). LDH release assay also
confirms that MCD enhanced the growth inhibitory effect
of tamoxifen (Additional file 2: Figure S1). In addition, we
found that coefficient of drug interaction (CDI) was less than
0.9 for A375 and B16F10 cells, suggesting that tamoxifen
and MCD combination synergistically inhibited proliferation
of A375 and B16F10 cells. (Additional file 1: Table S2).
On the contrary, no significant alteration in cell survival
and changes in the number of colonies were observed in
B16F1 cells (non-metastatic) treated with tamoxifen and
MCD combination (Additional file 3: Figure S2).
Methyl-β-cyclodextrin enhances tamoxifen induced
cytotoxicity through cell cycle arrest and induction
of apoptosis
Since tamoxifen in-combination with MCD influenced
cell survival, we performed cell cycle analysis and apoptosis
related experiments to further characterize synergistic effect
in A375 and B16F10 cells. When cells were treated with
tamoxifen and MCD combination, the percentage of cells
in Sub G0/G1 phase increased dramatically to ≥50% with
concomitant reduction in the population of cells in other
phases as compared to either agent alone (Figure 2A, D).
Further, we investigated the status of cell cycle regulatory
proteins, estrogen receptor alpha (ERα) and estrogen recep-
tor beta (ERβ) by Western blot analysis. In cells treated with
tamoxifen and MCD combination, significant reduction
in the levels of cell cycle regulatory proteins pRb, cyclin
D1, CDK1/2, CDK4 and ERα and up-regulation of ERβ
was detected (Additional file 6: Figure S5). Reduced cell
survival is a consequence of apoptotic death in cells
treated with tamoxifen and MCD combination as evident
by detection of enhanced internucleosomal cleavage of
DNA (Figure 2B, E), induction of PARP cleavage, up-
regulation of Bax and down regulation of Bcl-2 protein
levels in A375 and B16F10 cells (Figure 2C, F).
Cholesterol supplementation rescues methyl-β-cyclodextrin
enhanced susceptibility of cells towards tamoxifen
To correlate depletion of membrane cholesterol with
enhanced cytotoxic effect of tamoxifen, A375 and B16F10
cells were exposed to tamoxifen and MCD in the presence
or absence of cholesterol (100 μg/ml) supplemented
directly in the medium and cell survival was assessed
Figure 1 MCD augments antiproliferative activity of tamoxifen on tumor cells in vitro. Combination of tamoxifen and MCD exerts
synergistic effect on different cancer cell lines. (A-B) A375 and (D-E) B16F10 cells were treated with indicated concentrations of tamoxifen
together with MCD for 24 h. Data were presented as percentage of cell proliferation measured by MTT assay. (C and F) A375 and B16F10 cells
respectively were treated with indicated concentration of tamoxifen along with MCD. Long term clonogenic survival assay was performed and
colonies were assessed by Image J software. (G and H) MCF-7 and HeLa cells respectively were treated with indicated concentrations of
tamoxifen together with MCD for 24 h. Data were presented as percentage of cell proliferation measured by MTT assay. Bar graph represents the
Mean ± SD of an experiment done in triplicate (*P≤ 0.05, **P ≤ 0.001, ***P≤ 0.0001).
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treated with tamoxifen and MCD combination. Tamoxifen
induced MCD potentiated cell death was completely
abrogated in cells cultured in cholesterol supplemented
medium (Figure 3A, D). Also, in cells supplemented with
cholesterol, the number of surviving colonies was similar
to untreated cells (Figure 3B, E and C, F). Total cellular
cholesterol level was reduced by >25% in the cells treated
with tamoxifen and MCD combination as compared
to tamoxifen alone (Additional file 7: Figure S6).
Normalization of cholesterol level in MCD treatedcells was achieved by culturing cells in cholesterol rich
medium (Additional file 7: Figure S6). Similarly, in mice fed
with 2% cholesterol, serum cholesterol level was elevated
by day 15 to day 30 (data not shown).
Co-administration of methyl-β-cyclodextrin and tamoxifen
retards melanoma progression
Having confirmed the enhanced effectiveness of tamoxifen
in-combination with MCD in vitro in melanoma cells, we
examined in vivo effects of this combination treatment
against B16F10 cells isografted in C57BL/6J mice. After
Figure 2 MCD enhances the susceptibility of A375 and B16F10 cells to tamoxifen by alteration in cell cycle and DNA fragmentation.
A375 and B16F10 cells were treated with indicated concentration of tamoxifen along with MCD. (A and D) Display of the percentage cells in
different phases of cell cycle by flow cytometry. (B and E) The treated cells were assayed by DNA fragmentation. (C and F) Whole cell lysate
were subjected to Western blotting and expression level of PARP, Bcl-2 and Bax was detected. GAPDH served as a loading control. Relative folds
(RF) values are expressed in arbitrary unit. Data are representative of experiments performed in triplicate.
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approximately 80 mm3, mice were randomly divided into
four groups of normal diet and two groups of cholesterol
supplemented diet. Animal experiments were performed
according to layout (Figure 4A). Tumor volumes of mice
were measured every alternate day. Tumors progressed
very slowly in normal diet fed mice administered with
tamoxifen and MCD combination as compared to ei-
ther agent alone (Figure 4B). No significant reduction
in tumor volume was detected in cholesterol supplemented
diet fed mice administered with tamoxifen and MCD
combination, and the tumor progression was similar to
control mice (Figure 4C). The excised tumor size and
tumor weight diminished by approximately 75% in nor-
mal diet fed mice administered with tamoxifen and
MCD combination suggesting a synergistic effect of the
combination (Figure 4D, E). In all the groups of mice
administered with tamoxifen and MCD combination or
either agent alone, body weight remained unaffected and
no gross symptoms of toxicity or possible adverse side
effects were detected upon visual inspection (Figure 4F).In order to investigate the precise mechanism of action
of tamoxifen and MCD combination, the tumors were
processed for immunohistochemical expression of PCNA
(proliferation marker) and CD31 (angiogenesis marker).
Diminished PCNA staining was detected in tumor sections
of mice administered with tamoxifen and MCD combin-
ation as compared to untreated and either agent alone
treated mice (Figure 4G (i) a-d). Angiogenesis is a critical
factor for tumor growth and development and CD31 is
widely used biomarker to highlight the degree of neoan-
giogenesis. CD31 expression is significantly reduced in
tumor sections of mice administered with tamoxifen and
MCD combination (Figure 4G (ii) a-d). The quantitative
data of immunohistochemical analysis is depicted in
Figure 4H. Furthermore, by hematoxylin and eosin staining,
we found extensive necrotic areas in tumor sections of mice
administered with tamoxifen and MCD combination
compared to either agent alone (Figure 4G (iii) a-d).
There were no apparent pathological abnormalities in
the organs like liver, kidney, lung and heart of mice due
to treatment with tamoxifen and MCD combination
Figure 3 MCD treatment enhances the susceptibility of cells to tamoxifen induced cell death and cholesterol treatment reverses the
effect. (A and D) A375 and B16F10 cells were treated with indicated concentration of tamoxifen in- combination with MCD and cholesterol. Data
were presented as percentage of cell proliferation measured by MTT assay. (B and E) Long term clonogenic survival assay. (C and F) Relative
quantitation of colonies by Image J software in different fields. Bar graph in MTT assay represents the Mean ± SD of experiments done multiple
times in triplicate (*P≤ 0.05, **P ≤ 0.001, ***P≤ 0.0001).
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that antitumor effect of tamoxifen in- combination with
MCD is a cumulative effect of increased antiproliferative
and anti-angiogenesis activities.
Mass spectrometric quantitation of tamoxifen in tumors
and organs
To investigate whether combination treatment enhances
tamoxifen uptake, we performed mass spectrometry
analysis in tumors, liver, kidney and serum samples of
mice administered with tamoxifen and MCD combination
and tamoxifen alone. Retention time (RT) for pure
tamoxifen was determined to be 10.3 min (Figure 5A)
and extracted ion chromatogram (XIC) of selected
fragment ion was used to develop standard curve
(Additional file 9: Figure S8). The fragmentation pattern
of tamoxifen is shown in Figure 5B. Mass spectrometric
analysis revealed presence of higher amount (7.2 fold)
of tamoxifen in the tumors of mice administered with
tamoxifen and MCD combination as compared to tam-
oxifen alone (Figure 5C). The level of tamoxifen in the
liver and kidney of mice administered with tamoxifenand MCD combination was 30-50% lower than in mice
administered with tamoxifen alone (Figure 5D, E). No de-
tectable level of tamoxifen was detected in the plasma of
mice from either treatment group (data no shown).
Cav-1 level and Akt/ERK molecules facilitate
methyl-β-cyclodextrin enhanced tamoxifen cytotoxic effects
We have previously reported that MCD potentiates the
effect of Carb and 5-FU by reducing activation of Akt
and decreasing Bcl-2 level in breast cancer cells [21].
Also, association of Cav-1 and Akt/ERK signaling pathways
with the mode of action of chemotherapeutic drugs has
been reported earlier [24,25]. In tumors lysates from nor-
mal diet fed mice administered with tamoxifen and MCD
combination, Cav-1, pAkt and pERK levels were reduced
(Figure 6D). Similarly, Cav-1, pAkt and pERK levels were
also reduced in A375 and B16F10 cells treated with tam-
oxifen and MCD combination (Figure 6B, C respectively,
highlighted by rectangular block). No changes in the levels
of these proteins were detected in B16F1 cells treated with
tamoxifen and MCD combination as compared to either
agent alone (Additional file 3: Figure S2D). Additionally,
Figure 4 Effect of tamoxifen and MCD on isografted mouse tumor model. Mice were pre administered with 64 mg/kg of MCD
(oral/alternative day) and 20 mg/kg of tamoxifen (i. p./alternative day). Control mice were administered with equal volume of normal saline on
the same treatment day. (A) Experimental layout of in vivo study. (B) Tumor initiation and progression after drug administration in control and
treated mice. (C) Changes in tumor volume in cholesterol supplemented mice after drug administration. (D and E) Bar graph (Mean ± SD)
showing average tumor volume and tumor weight respectively of mice fed with normal diet, on the day of sacrifice (day 32). (F) Changes in
body weight in mice during the course of treatments. (G) Representative panel of immunohistochemistry analysis of (i) PCNA, (ii) CD31 in the
tumors of mice administered with MCD, tamoxifen and MCD along with tamoxifen. Magnification (10×) with inset at (40×).(iii) H&E staining of tumor
of untreated and treated mice developed with DAB (brown) and counterstained with hematoxylin nuclei (blue). (H) Bar graph (Mean ± SD) showing
quantitation of average number of PCNA positive cells selected from multiple fields by Image J software. (*P≤ 0.05, **P≤ 0.001, ***P≤ 0.0001).
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B16F10 cells as well as tumors following treatment
with tamoxifen and MCD combination (Figure 6A).
Finally, we tested whether replenishment of mem-
brane cholesterol by culturing cells in cholesterol rich
medium would cause reversal of these alterations.Interestingly, cholesterol replacement prevents decrease in
Cav-1, pAkt and pERK levels (Figure 6B, C respect-
ively, highlighted by rectangular block) in the A375
and B16F10 cells as well as in tumors of mice fed with
cholesterol and treated with tamoxifen and MCD combin-
ation (Figure 6E, F).
Figure 5 Detection of tamoxifen in tumor of mice administered with tamoxifen and MCD. (A) Extracted ion chromatogram (XIC) of
selected fragment ion (m/z 72.0808) of tamoxifen. (B) MS/MS fragmentation pattern of tamoxifen. (C) Quantitation of tamoxifen by area under
curve of tumor. (D and E) Quantitation of tamoxifen by area under curve of liver and kidney, respectively. Values of tumors are represented as
mean ± SD (n = 3). For liver and kidney values are mean of two samples.
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Due to accompanying drug resistance, effective therapeutic
option to treat melanoma is still a medical challenge and
nearly no improvement has been made for past thirty years.
In this study, we investigated the growth inhibitory effect of
tamoxifen in-combination with MCD in vitro and in iso-
grafted mice model of melanoma. We have demonstrated
for the first time that only tamoxifen in-combination with
MCD was effective in inhibiting the proliferation of melan-
oma cells regardless of Ras-Raf mutation status (Figure 1).
Tumor recurrence and metastases due to activating mu-
tation in the mitogen-activated kinase (MAPK) pathway
attributed to high mortality rate in melanoma patients.
Mutation in MAPK enrolls enzyme Ras and Raf signalling
cascade that leads to oncogenic cell proliferation and
escape from apoptosis [4]. While human melanoma cell
line (A375) carries BRAFV600E mutation and murine mel-
anoma cell line (B16F10) accommodate distinct patterns of
mutation in Ras gene with no active mutation in B-Raf
oncogene [26]. Therefore, both human and murine mel-
anoma cell lines were used to address the therapeuticoutcome of tamoxifen in-combination with MCD. These
mutational events are linked to activation of ERK and Akt
and the high occurrence of deregulation pathways thus
providing a rationale for the development of target based
chemotherapeutics for the treatment of melanoma [27].
Although, medical fraternity aims to formulate thera-
peutic strategies toward targeting mutated B-Raf/N-Ras,
its downstream molecules ERK and Akt have not been
tested [28,29]. Recently, the introductions of BRAF in-
hibitors and new immunotherapies have provided more
efficient treatment options with negligible toxicity [30].
Studies have shown that various signalling molecules
enriched on the lipid rafts of plasma membrane are as-
sociated with a number of biological processes and their
disruption impairs these signaling events [31,32]. Hence,
various components of plasma membrane have been a
promising target for cancer chemotherapy. Cholesterol, an
important component of lipid rafts, maintains the stability
and architecture of cell membrane. Its accumulation has
been reported in cancers such as prostate and oral cancer
[33,34]. Also, cholesterol metabolism is highly dysregulated
Figure 6 MCD potentiates the effect of tamoxifen by altering Cav-1 levels and Akt/ERK signaling. (A) Cav-1 mRNA levels were determined
by semi-quantitative RT-PCR. A375, B16F10 cells and tumor from mice treated with indicated concentration of tamoxifen along with MCD, were
processed for RT-PCR. β-actin was used as a loading control. (B and C) A375 and B16F10 cells, respectively, were treated with indicated
concentration of tamoxifen in- combination with MCD and cholesterol, and whole cell lysate were subjected to Western blotting and expression
level of Cav-1, pAkt, Akt, pERK and, ERK was assessed. (D and E) Tumor bearing mice were exposed to normal diet and cholesterol supplementation
respectively, were treated with indicated dose of MCD and tamoxifen, and tumor lysates were subjected to Western blotting and expression level of
Cav-1, pAkt, Akt, pERK and, ERK was assessed. GAPDH served as a loading control. (F) Schematic diagram of proposed mechanisms of MCD
potentiating the effect of tamoxifen and its abrogation by cholesterol supplementation.
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[35,36]. Amount of cholesterol present in the lipid rafts
of cell membrane influences trafficking of drugs and
other molecules through diffusion or receptor meditated
uptake [17]. In these contexts, cholesterol depleting agents,
cyclodextrins, are gaining importance in pharmaceutical
industries because of their effectiveness in enhancing thebioavailability and solubility of drugs [37,38]. MCD is a
frequently used FDA approved cyclodextrin to disrupt
lipid raft. Depletion of cholesterol from the plasma
membrane by MCD leads to modification of membrane
permeability thereby altering the signalling and the trans-
port of many molecules in cells [39-42]. Also, it is been re-
ported to cause apoptosis and caveolae internalization in
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oid carcinoma cells [43]. Present study provides evidences
that depletion of cholesterol from the membrane sensitizes
cells towards tamoxifen mediated cell death through
down regulation of Cav-1 and reduced phosphorylation
of Akt/ERK. Additionally, we show that MCD not only
potentiated the cytotoxic effects of tamoxifen in melanoma
cells in vitro (Figure 1) but also in B16F10 isografted mice
model (Figure 4).
Tamoxifen alone or in-combination with other che-
motherapeutic drugs has been reported to show poor
response rate in the treatment of melanoma [15,16]. In
this study, MCD was used as a tool to enhance the
cytotoxic effect of tamoxifen, and we found that this
combination treatment synergistically inhibited the prolif-
eration of melanoma cells. In vitro combination of tamoxi-
fen and MCD efficiently induced DNA fragmentation and
arrest in G1 phase of cell cycle (Figure 2) in A375 and
B16F10 cells. In vivo, we demonstrated that combination
of tamoxifen (20 mg/kg) and MCD (64 mg/kg) significantly
suppresses the tumor growth of mice as compared to either
agent alone with no apparent body weight loss and toxicity
to vital organs. The reduction in tumor size is primarily
due to enhanced antiproliferative and antiangiogenic effect
of combination treatment. Our results are in agreement to
the previous report wherein the decrease in the expression
of PCNA and CD31 has been correlated with reduction of
tumor size and overall disease free survival [44]. Quantita-
tion of tamoxifen in tumor samples by mass spectrometry
highlights the fact that reduction of tumor size was essen-
tially achieved because of increase in tamoxifen levels in
the tumor of mice administered with tamoxifen and MCD
combintaion as compared to tamoxifen alone (Figure 5C).
Concomitantly, the increased drug uptake specifically in
tumor reduces the accumulation of tamoxifen in liver and
kidney and thus it is likely to be less toxic to the organs,
which is a major concern of chemotherapy (Figure 5D, E).
Akt and ERK are major regulators of cell survival path-
ways governed by growth factors and various cytokines
[45]. Activation of PI3K/Akt or ERK pathways are associ-
ated with cell differentiation, cell proliferation and resist-
ance to apoptosis in various cancers including melanoma
[46-48]. Cav-1 is an important player for the regulation of
cellular cholesterol homeostasis, a process that controls
the accumulation of cholesterol on cell membrane. In
Cav-1 knock-out mice, depleted level of free choles-
terol on the surface of mouse embryonic fibroblast and
mouse peritoneal macrophages has been reported [49].
In an earlier study, we have reported a positive correlation
between Cav-1 levels to rapid progression of melanoma in
mice fed with high fat diet [50]. Cav-1 is known to exert
direct or indirect effect on the activation of Akt and
ERK pathways [24,25]. Thus, it is likely that decrease in
Cav-1 levels acts as an upstream event in deactivation ofintrinsic Akt and ERK growth stimulatory signals in
highly metastatic melanoma cells (A375 and B16F10)
whereas in non-metastatic melanoma cells (B16F1) no
such effect was detected (Figure 6B, C, Additional file 3:
Figure S2D respectively). Our findings indicate that choles-
terol supplementation prevented MCD potentiated tamoxi-
fen cell death in vitro as well as in vivo (Figures 3 and 4) by
reversing the molecular alterations as shown in schematic
model (Figure 6F).
Conclusions
The present findings emphasize the fact that cholesterol
depleting agent, MCD sensitizes highly metastatic melan-
oma cells towards tamoxifen treatment. Combinatorial
treatment of tamoxifen and MCD induces cytotoxicity by
causing cell cycle arrest, induction of apoptosis and de-
creases tumor growth in vivo. Taken together, our results
strongly provide the evidence that tamoxifen in- combin-
ation with MCD could have potential implications in mel-
anoma treatment as well as other solid tumors.
Material and methods
Drugs, chemicals and antibodies
Tamoxifen (TAM), methyl β-cyclodextrin (MCD), choles-
terol (CH) and methylthioazole-tetrazolium (MTT) were
purchased from Sigma-Aldrich (Sigma Aldrich, MO). TAM
and MCD were dissolved in ethanol and water respectively
to prepare 100 mM stock and further diluted in culture
medium. Antibodies against pAkt, Akt, pERK, ERK, Cav-1,
PARP, Bax, Bcl-2, Cdk4, Cdk1/2, cyclin D1, pRb, Rb, ERα,
ERβ and GAPDH were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA).
Cell culture conditions
A375 (human melanoma), B16F10 (murine melanoma)
and B16F1 (non metastatic melanoma), HeLa (cervical)
and MCF-7 (breast) cancer cells were purchased from
American Type Culture Collection (ATCC) Manassas,
VA and maintained in our in-house Cell Repository. Cells
were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) with 10% heat inactivated FBS (Hyclone, UT),
Penicillin (100U/ml), Streptomycin (100 μg/ml) (Invitrogen
Life Technologies, CA) and incubated at 37°C in 5% CO2
incubator (Thermo Scientific, NC).
Mode of MCD and tamoxifen combination treatment
Cells were pre-exposed to MCD for 4 h. Thereafter, cells
were washed with fresh medium and then medium con-
taining indicated concentrations of tamoxifen was added
for 24 h. For cholesterol (CH) treatment, cells were in-
cubated with MCD for 4 h, washed thereafter and fresh
medium containing cholesterol (100 μg/ml) was added.
Four hours later, tamoxifen was added and cells were
incubated for further 24 h.
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Cells (5 × 103/well) were plated in 96-well plates and
allowed to adhere for 24 h at 37°C. Next day, cells were
treated with varying concentration of tamoxifen for 24 h
with or without MCD or cholesterol as described earlier
in mode of treatment. Viability of cells was measured by
MTT assay as described [50]. Any synergistic effect
resulting from combination of drugs was calculated by
coefficient of drug interaction (CDI) as follows:
CDI ¼ AB= A Bð Þ:
AB is the ratio of the combination of drug groups to
control group; A or B is the ratio of the single drug group
to control group. The CDI value > 1: antagonistic effect,
CDI = 1: additive and CDI < 1: synergistic effect [51].
Whole cell lysate preparation and western blotting
Whole cell lysates were prepared and immunoblotting
was performed as described previously [50].
Long term clonogenic survival assay
Cells (5 × 103/well) were plated in 12-well plates and
allowed to adhere for 24 h. Cells were treated as per experi-
mental requirement. After 24 h of treatment medium was
replaced with fresh medium and cells were allowed to grow
for 10–15 days. After completion of experiment, surviving
cells were washed with PBS and fixed with chilled 3%
paraformaldehyde. The surviving cells were stained with
0.05% crystal violet dye and images were captured by cam-
era (Olympus, Tokyo, Japan). The number of colonies was
counted by using Image J software.
RNA extraction, cDNA synthesis and quantitative RT-PCR
Cells were treated with MCD and tamoxifen as described
earlier. Also, tumor sections of mice were stored at −80°C
in TRIzol reagent (Invitrogen, CA) after excision until
processing for RT-PCR. Total RNA from the cells and tu-
mors was extracted as per the manufacturer’s instructions
(TRIzol reagent Invitrogen, CA). cDNA synthesis and
RT-PCR were performed as described earlier [24]. Primer
pairs used are as follows: Cav-1 5′-AGA CTCGGAGGGA
CATCTCTACAC-3′ (F), 5′-ACTGTGTGTCCCTTCTG
GTTCTG-3;(R) and for β-Actin 5′-ATCTGGCACCAC
ACCTTCTACAATGAGCTGCG-3′ (F), 5′-CGTCATAC
TCCTGCTTGCTGATCCACATCTGC-3′ (R). The anneal-
ing temperature used for both Cav-1 and β-actin was 58°C.
Cholesterol estimation
Cells (3 × 105) were plated in 35 mm culture dish and
treated with MCD, cholesterol and tamoxifen as described
earlier. Cells were lysed in PBS containing 2% Triton X-100
for 10 min. After centrifugation (12,000 rpm, 15 min),
resulting supernatant was used for cholesterol estimation.For cholesterol release assay, medium was collected and
concentrated by using Speed Vac (Thermo Savant, MA). In
animal experiments blood was collected from mice fed with
2% cholesterol by approved tail cap method. Cholesterol
was estimated by using kit with sensitivity range of 1 mg/
dL–750 mg/dL purchased from Spinreact (Girona, Spain)
as per the manufacturer’s instructions.
LDH release assay
Cells (3 × 105) were plated in 35 mm culture dish and
treated as described earlier, medium was collected and LDH
release was measured according to manufacturer’s protocol
using LDH activity assay kit (Spinreact, Girona, Spain).
Cell cycle analysis
Cells (3 × 105) were plated in 35 mm culture dish and
treated with 2.5 mM of MCD for 4 h, washed twice with
fresh medium and further grown in culture medium for
additional 12 h. In experiments related to MCD and
tamoxifen, cells were treated with both the drugs as
described earlier. Cells were collected and processed
for cell cycle analysis as described elsewhere [52].
Agarose gel electrophoresis
Cells (3 × 105) were plated in 35 mm culture dish and
treated with MCD and tamoxifen as described earlier
and agarose gel electrophoresis and LDH release assay
performed as described elsewhere [53].
Mass spectrometric analysis
Tamoxifen was extracted from tumors, plasma of tumor
bearing mice and from liver, kidney of mice injected with
MCD and tamoxifen combination according to described
method [54]. Tamoxifen was quantified in biological
samples in duplicate by selected reaction monitor-
ing using hybrid quadrupole Orbitrap mass analyzer
(Q-Exactive, Thermo Scientific, Germany) in a high
resolution mode. Briefly, 5 μL of the final extract was
injected to Accela UPLC (Thermo Scientific, Germany)
and the separation was performed using a reverse phase
Hypersil Gold C18 5 μm column (150 × 4.6 mm) with a
flow rate of 500 μL/min of binary solvent system consist-
ing of mobile phase A: water with 0.1% formic acid and
mobile phase B: acetonitrile with 0.1% formic acid. The
mass spectra were acquired in high resolution (70000)
mode by using Xcalibur and data was processed by Quant
software (Thermo Scientific, Germany). The method
consisted of full scans and targeted MS/MS of selected
precursor ion at a defined mass and retention time accord-
ing to described settings [55]. The standard curve was
developed by plotting the log10 value of area under curve
(AUC) of the selected fragment of tamoxifen (m/z 72.0808)
by extracted ion chromatogram (XIC) against log10 value
of serial dilutions of pure tamoxifen ranging from 50 fg to
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paring the XIC of selected fragment ion (m/z 72.0808).
In vivo experiments
All animal experiments were performed according to the
Institutional guidelines, following a protocol approved
by the Institutional Animal Ethic Committee (IAEC).
Five to six weeks old male C57BL/6J (weight 20 ± 2 g)
were acquired from experimental animal facility (EAF)
of National Centre for Cell Science, Pune, India. B16F10
cells (1 × 106/mice) were injected subcutaneously on the
right flank of each mouse. After 12–14 days, palpable
tumor bearing mice were randomly divided into four
groups (n = 6). Group (a), mice administered with ve-
hicle control, group (b), mice administered with MCD
(64 mg/kg, intraperitoneally), group (c), mice administered
with tamoxifen (20 mg/kg, orally) and group (d), mice ad-
ministered with MCD and tamoxifen. MCD and tamoxifen
were dissolved in sterile water and ethanol respectively and
further diluted with PBS. In cholesterol feeding experiment,
mice were fed with chow containing 2% cholesterol for
30 days and total serum cholesterol was measured every
15 days. Subsequently, mice were divided into two groups.
Group one referred as control group whereas group two
mice were administered with MCD and tamoxifen. Both
the groups of mice were fed with cholesterol during the
course of experiment. At the end of experiment, mice were
sacrificed by cervical dislocation and tumors excised. Size
of tumors during the course of experiment was measured
using caliper in two dimensions. Tumor volume (mm3)
was calculated according to the formula AXB2X0.52
(A, length; B, width; all parameters in millimeters). For
immunohistochemical and histopathological studies,
sections of tumors and organs were fixed into 10%
paraformaldehyde immediately after excision. Remaining
part of tumors was stored at −80°C for RT-PCR and lysate
preparation used for Western blotting.
Immunohistochemical and histopathological studies
Fine sections (4 μm) were prepared from formalin fixed
paraffin embedded tumor tissue and fixed on glass slides
(Safeline Histopathology, Pune, India). For immunohis-
tochemistry, slides were deparaffinized by xylene solution
twice for 10 min and subsequently dehydrated in
graded alcohol (100%, 95%, 70% and 50%). Endogenous
peroxidase activity was blocked by 0.01% H2O2. For
antigen retrieval, slides were boiled in sodium citrate
buffer (0.01 M, pH 4.5) at 100°C for 10 min and allowed
to cool at room temperature. BSA (0.2%) was used for
blocking for 1 h. After washing with TBST, slides were
probed with CD31 and PCNA antibodies specific for IHC
(Santa Cruz Biotechnology, CA) and incubated at 4°C
overnight. Slides were washed with TBST and probed with
compatible HRP-conjugated secondary antibody for 3 h.Slides were stained with diaminobenzidine (DAB) for
10 min followed by counterstaining with hematoxylin
and eosin. Slides were mounted and analysis of indi-
cated proteins was performed. For histopathology,
deparaffinized slides were stained with hematoxylin and
eosin and microscopic analysis for cell density, cellular
morphology and necrosis was performed and images
were captured by DP71 camera attached with micro-
scope (Olympus, Tokyo, Japan). The staining of cells
was quantified by Image J software.Statistical analysis
Statistical analysis and data comparison were performed
by Student’s 2-tailed unpaired t-test by using Sigma Plot
software (Systat Software Inc, CA). The values of P <0.05
were considered statistically significant. Quantitation
of colonies and relative staining of PCNA of cells were
done by using NIH Image J software (Image J Freeware;
http://rsb.info.nih.gov/ij/).Additional files
Additional file 1: Table S1. IC50 values of tamoxifen for A375, B16F10
and B16F1 cells. Table S2. Drug interaction was analyzed by calculating
coefficient of drug interaction (CDI) as described in materials and
method section.
Additional file 2: Figure S1. Low-dose treatment of MCD does not
induce toxicity in A375 and B16F10 cells. (A and D) Cells were treated
with indicated concentration of tamoxifen and MCD and cells were
subjected to MTT assay. (B and E) Display of different phases of cell cycle
represented as percent cell population. (C and F) LDH release assay. Bar
graph represents the mean ± SD of an experiment done in triplicate.
(*P ≤ 0.05, **P≤ 0.001, ***P ≤ 0.0001).
Additional file 3: Figure S2. Tamoxifen and MCD combination
treatment does not affect survival of B16F1 cells (non-metastatic).
(A) Cells were treated with indicated concentration of MCD for 1 and 4 h,
(B) Cells were treated with indicated concentration of tamoxifen and
MCD for 24 h and cells were subjected to MTT assay. (C) Clonogenic
survival assay. (D) Representative Western blots showing protein level of
indicated molecules. In MTT assay, bar graph represents the mean ± SD
of an experiment done in triplicate.
Additional file 4: Figure S3. MCD does not affect survival of A375 and
B16F10 cells treated with various chemotherapeutic drugs. (A-C) A375,
(D-F) B16F10 cells were treated with indicated concentration of MCD
followed by treatment with either of carboplatin (Carb), doxorubicin
(DOX) or 5-flurouracil (5-FU) for further 24 h and cells were subjected to
MTT assay. Bar graph represents the mean ± SD of an experiment done
in triplicate. (*P ≤ 0.05, **P≤ 0.001, ***P ≤ 0.0001).
Additional file 5: Figure S4. MCD potentiates cell toxicity of higher
doses of DTIC to melanoma cells. (A and C) A375 and B16F10 cells were
treated with indicated concentration of MCD and DTIC for 24 h, and cells
were subjected to MTT assay. (C and D) Clonogenic survival assay. Bar
graph represents the mean ± SD of an experiment done in triplicate.
Additional file 6: Figure S5. MCD enhances the susceptibility of
melanoma cells to tamoxifen by altering cell cycle regulatory molecules.
A375 and B16F10 cells were treated with indicated concentration of
tamoxifen and MCD. Cell lysates were prepared and proteins were
resolved on 10-12% SDS-PAGE and processed for Western blotting
analysis. (A-D) Representative Western blots showing protein level of
indicated cell cycle regulatory molecules.
Mohammad et al. Molecular Cancer 2014, 13:204 Page 12 of 13
http://www.molecular-cancer.com/content/13/1/204Additional file 7: Figure S6. Total cholesterol (CH) estimation in cells
and in spent medium owing to the drug treatment. Cells were treated
with indicated concentration of tamoxifen and MCD and cholesterol was
estimated in whole cell extract (A and D) and in culture medium (C and F).
(B and E) cells were treated with indicated concentration of MCD, tamoxifen
as well cholesterol, level of cholesterol was estimated in cell lysate.
Bar graph represents the mean ± SD of an experiment done in
triplicate (*P ≤ 0.05, **P ≤ 0.001, ***P ≤ 0.0001).
Additional file 8: Figure S7. Histopathological analysis of major vital
organs. Liver, kidney, lungs and heart tissues were fixed in 4%
formaldehyde. The processed tissues sections were stained by
hematoxylin and eosin (H&E) (magnification, ×400; scale bars, 100 μm).
Additional file 9: Figure S8. HPLC profile of standard curve of different
concentration of tamoxifen. Standard curve of tamoxifen was generated
by plotting log10 (AUC) Vs log10 (concentration of tamoxifen).
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